ArticleInternational journal of rheumatic diseases2026
Hematological Indices as Biomarkers in Patients With Rheumatoid Arthritis but Normal ESR/CRP Receiving Biological/Targeted Synthetic DMARDs.
Article in International journal of rheumatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Concurrent Response Tracking to Clinically Actionable Biomarkers in Rheumatoid Arthritis: Comment on Jhou et al.International journal of rheumatic diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesEvidence indicates that hematological indices, such as neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), and neutrophil-to-hemoglobin and lymphocyte (NHL), are valuable for assessing disease activity in rheumatoid arthritis (RA). This study investigated their potential as biomarkers for monitoring treatment response and disease improvement in RA patients receiving biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs).
methodsA retrospective analysis was conducted on 308 active RA patients receiving IL-6 receptor inhibitors, TNF-alpha inhibitors, cytotoxic T lymphocyte-associated antigen-4-Ig (abatacept), or Janus kinase inhibitors. Hematological indices were collected at baseline and 6 months post-treatment.
resultsSignificant reductions in NLR, SII, and NHL were observed after initiation of b/tsDMARD therapy. These changes correlated with improvements in DAS28-ESR and discriminated good/moderate responders from non-responders. Each index predicted a > 1.2-point reduction in DAS28-ESR (area under the curve values ranging from 0.709 for NHL to 0.732 for SII). Adding any of these hematological indices to ESR increased sensitivity to 62.0%-63.4% versus 53.4% for ESR alone. Among patients with active disease but normal ESR/CRP, these indices (sensitivity 54.8%-66.1%) better reflected disease burden and treatment response than traditional markers (sensitivity 29.0%), which changed minimally despite DAS28-ESR improvement.
conclusionNLR, SII, and NHL are potential biomarkers for assessing treatment response in RA patients receiving b/tsDMARDs. Used alongside ESR, these indices improve evaluation of disease improvement. Notably, in clinically active patients with normal ESR/CRP levels, these indices captured treatment-related change that traditional acute-phase reactants did not, supporting their use as alternative or complementary response indicators in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.